Relypsa announces data published in NEJM for pivotal phase 3 program of Patiromer FOS
Relypsa announced results from the pivotal Phase 3 program of the company's lead product candidate, Patiromer for Oral Suspension, were published in NJEM. The program was conducted under Special Protocol Assessment to evaluate safety and efficacy of Patiromer FOS for treatment of HK in CKD patients. November 21, 2014